Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466546 | 0.86 | GAA (0.57) | GAAMOGAT2CREBBPPOLBHTT | |
| SCHEMBL11337711 | 0.83 | GAA (0.55) | GAAMOGAT2CREBBPPOLBMEN1 | |
| SCHEMBL9511664 | 0.79 | GAA (0.57) | GAAMOGAT2CREBBPMEN1LMNA | |
| SCHEMBL11327486 | 0.79 | GAA (0.57) | GAAMOGAT2CREBBPPOLBMEN1 | |
| SCHEMBL9511671 | 0.79 | GAA (0.57) | GAAMOGAT2CREBBPMEN1LMNA | |
| SCHEMBL24776758 | 0.78 | NR3C2 (0.39) | GAAMEN1MAPTKMT2ALTA4H | |
| SCHEMBL7297099 | 0.78 | NR3C2 (0.41) | GAALTA4HDRD3 | |
| SCHEMBL7300283 | 0.78 | CHEK1 (0.38) | GAADRD3 | |
| SCHEMBL8544441 | 0.78 | GAA (0.43) | GAACREBBPHTTMEN1MAPT | |
| SCHEMBL7298355 | 0.78 | GAA (0.52) | GAAMOGAT2POLBHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0666260-B1 | 3-(2-aminoethyl)-4-3-(trifluoromethyl)benzoyl-3,4-dihydro-2H-1,4-benzoxazine derivatives, their preparation and use in therapy | SYNTHELABO (FR) | 1999-08-04 | — | — | EP | claimed |
| EP-0614893-B1 | Benzoxazine derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1998-05-27 | — | — | EP | claimed |
| EP-0666260-A1 | 3-(2-aminoethyl)-4-3-(trifluoromethyl)benzoyl-3,4-dihydro-2H-1,4-benzoxazine derivatives, their preparation and use in therapy | SYNTHELABO (FR) | 1995-08-09 | — | — | EP | claimed |
| CN-1099032-A | Benzoxazine derivatives, their preparation and their use in medicine | SYNTHELABO (FR) | 1995-02-22 | — | — | CN | claimed |
| EP-0614893-A1 | Benzoazine derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1994-09-14 | — | — | EP | claimed |
| US-9464063-B2 | Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-20140018358-A1 | BENZO [B] [1,4] OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2014-01-16 | — | — | US | disclosed |
| EP-0666260-B1 | 3-(2-aminoethyl)-4-3-(trifluoromethyl)benzoyl-3,4-dihydro-2H-1,4-benzoxazine derivatives, their preparation and use in therapy | SYNTHELABO (FR) | 1999-08-04 | — | — | EP | disclosed |
| EP-0614893-B1 | Benzoxazine derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1998-05-27 | — | — | EP | disclosed |
| US-5550125-A | BRAIN DISORDERS | SYNTHELABO (FR) | 1996-08-27 | — | — | US | disclosed |
| CN-1109880-A | 3-(2-aminoethyl)-4-[3-(trifluoromethyl) benzoyl]-3,4-dihydro-1,4-benzoxazine derivative and preparation of same | SYNTHELABO (FR) | 1995-10-11 | — | — | CN | disclosed |
| US-5447928-A | Antiischemic agents and nervous system disorders | SYNTHELABO (FR) | 1995-09-05 | — | — | US | disclosed |
| EP-0666260-A1 | 3-(2-aminoethyl)-4-3-(trifluoromethyl)benzoyl-3,4-dihydro-2H-1,4-benzoxazine derivatives, their preparation and use in therapy | SYNTHELABO (FR) | 1995-08-09 | — | — | EP | disclosed |
| EP-0614893-A1 | Benzoazine derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018358-A1 | BENZO [B] [1,4] OXAZIN DERIVATIVES AS CALCIUM SENSING RECEPTOR MODULATORS | CASR, RYR1, RYR2 | GAA 1225/4885MOGAT2 3519/4885CREBBP 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.